Swiss Rockets

Aurion Biotech, a spin off of CorneaGen, is a clinical-stage biotech company focused on developing a platform of cell gene therapies and biologics that restore sight in patients suffering from partial to total vision loss.By June 2021, the company had been established as a division of CorneaGen. However, in April 2022, the company raised financing from investors and became an independent business unit of CorneaGen.In April 2022, the company announced it secured a USD 120 million financing

Epicrispr Biotechnologies Inc (Epic Bio) is a biotech company is focusing on developing therapies to dynamically control gene expression and treat complex disease

Hubble Therapeutics开发一种基因治疗平台，用于治疗一种罕见的遗传性眼病，这种疾病通常在婴儿期开始出现严重的进行性视力损害。该公司的专利基因疗法治疗莱伯先天性黑朦（leber congenital amaurosis），这是一种罕见的遗传性眼病，使患者能够逆转这种损失，并通过一次治疗恢复视力。